Article By:
Zacks Investment Research
Monday, December 11, 2023 6:43 AM EDT
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old defense mechanism bacteria use to battle viruses.
Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Looking forward to hearing more information about $EDIT. Company seems to operate in a very exiting and potentially fast growing new field.